SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
PLRX reported Third Quarter 2026 results. The price and volatility reaction is pending.
PLRXearnings

Earnings reactions, page 3

Pliant Therapeutics, Inc. (PLRX) Q3 FY2026 earnings

November 13, 2026 · SharpeIQ Research Desk

Reported results

  • Research and development expenses were $17.9 million in the third quarter of 2026, consistent with $17.9 million in the prior-year quarter.
  • General and administrative expenses were $7.8 million in the third quarter of 2026, compared to $10.3 million for the prior-year quarter.
  • Net loss was $24.4 million for the third quarter of 2026, compared to $26.3 million for the prior-year quarter.
  • Net loss per share - basic and diluted was $0.39 for the three months ended September 30, 2026, compared to $0.43 for the three months ended September 30, 2025.
  • Cash, cash equivalents and short-term investments were $142.6 million as of September 30, 2026.

Guidance

  • The Company expects its cash, cash equivalents and short-term investments of $142.6 million as of September 30, 2026 to be sufficient to fund operations to mid-2028.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →